Share price falls of 90% are mercifully rare in biopharma — but as Rezolute discovered Thursday, not entirely unknown.
The wholesale failure of the Phase 3 trial of the company’s only drug, which is intended to …
Welcome back to another edition of Endpoints Weekly. We’re barreling toward the holiday season, which means it’s time for an early programming note: Our newsletters
Eligible health centers purchased $81.4 billion in discounted drugs under the federal 340B program in 2024, an increase of 23% from the previous year as
An FDA staff analysis of the safety of pediatric Covid-19 shots has been finalized and sent to the agency’s vaccine and biologics head Vinay Prasad.
Health insurers are facing two colliding forces heading into 2026: Medical costs are challenging the way they do business, and major technology shifts are finally
As part of a batch of recommendations issued Friday, the European Medicines Agency’s human medicines committee (CHMP) recommended rejecting Anavex’s Alzheimer’s disease drug, issuing a
Share price falls of 90% are mercifully rare in biopharma — but as Rezolute discovered Thursday, not entirely unknown.
The wholesale failure of the Phase 3 trial of the company’s only drug, which is intended to …